News

The planned 46 patients have been enrolled and are currently undergoing treatment and follow-up. The primary objective of the multi-center, open-label Phase II study is to assess the

Under the terms of the agreement, Tessella and Cmed will ensure interoperability of Timaeus, the intelligent data acquisition and management system with Tessella Fates, Tessella’s fixed and adaptive

Prior to joining NeuroMetrix, Mr Christensen was the senior vice president of global sales at Stereotaxis. Prior to Stereotaxis, Mr Christensen was vice president for mid America zone

Most recently Dr Peake served as the secretary of veterans affairs and formerly as US army surgeon general. Dr Peake’s military and medical career also includes service as

Dr Lewis-Hall will be the senior physician in the company, responsible for enterprise-wide medical, patient safety, regulatory affairs and quality assurance as well as outreach to doctors and

Mr Tobin, who also will be joining Health Discovery Corporation’s (HDC) board of directors, will be responsible for strategic and operational leadership of HDC. Mr Tobin most recently

Fovea Pharmaceuticals, a French biopharmaceutical company, has reported positive results from its clinical proof-of-concept trial to assess the therapeutic effect of Prednisporin in patients with persistent allergic conjunctivitis.

Can-Fite BioPharma, an Israeli science-based biopharmaceutical company, has reported top line results from its Phase IIb study in rheumatoid arthritis patients which indicate that the study failed to

Tigris Pharmaceuticals, a drug development company, has initiated dosing in a Phase I clinical trial of GGTI-2418, a synthetic peptidomimetic inhibitor of geranylgeranyltransferase I that induces apoptosis by